Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | ALB | P02768 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | DGKA | P23743 | 1/20 | 0.42 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8210289 | 1.00 | ALDH1A1 (0.48) | ALDH1A1MCHR1LMNATDP1ALB | |
| Ammonia Solution, Strong SCHEMBL27383584 | 0.98 | ALDH1A1 (0.47) | ALDH1A1MCHR1LMNATDP1ALB | |
| SCHEMBL8208205 | 0.98 | ALDH1A1 (0.46) | ALDH1A1MCHR1LMNATDP1ALB | |
| SCHEMBL27659885 | 0.94 | ALDH1A1 (0.47) | ALDH1A1MCHR1LMNATDP1ALB | |
| Water SCHEMBL14635602 | 0.92 | KMT2A (0.46) | ALDH1A1MCHR1LMNATDP1ALB | |
| SCHEMBL10730060 | 0.92 | FAAH (0.48) | KMT2AMEN1 | |
| SCHEMBL9808856 | 0.92 | FAAH (0.48) | KMT2AMEN1 | |
| SCHEMBL1914560 | 0.92 | FAAH (0.48) | KMT2AMEN1 | |
| SCHEMBL7182276 | 0.89 | DGKA (0.43) | ALDH1A1LMNADGKACA1CA2 | |
| SCHEMBL7187298 | 0.89 | DGKA (0.43) | ALDH1A1LMNADGKACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118284604-A | Fused heterocycles as RIPK1 inhibitors | 比西切姆有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-117715905-A | Checkpoint kinase 1 (CHK 1) inhibitors and uses thereof | 无界生物公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-117545751-A | 2, 4-diaminopyrimidine derivatives as ULK1/2 inhibitors and their use | 生命爱科 | 2024-02-09 | — | — | CN | disclosed |
| CN-116574099-A | Phosphodiesterase inhibitors and uses | 南京征祥医药有限公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-116496279-A | Isotopically labelled trapidil derivatives | 希诺皮亚生物科学公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-116406356-A | Process for the preparation of 6- (4-nitro-phenoxy) -2H-pyridazin-3-one and 6- (4-amino-phenoxy) -2H-pyridazin-3-one derivatives as intermediates for thyroid hormone analogues | 马德里加尔制药公司 | 2023-07-07 | — | — | CN | disclosed |
| US-20230107941-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | VenatoRx Pharmaceuticals, Inc. | 2023-04-06 | — | — | US | disclosed |
| CN-115215923-A | Macrocyclic broad spectrum antibiotics | 豪夫迈·罗氏有限公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-114401719-A | Inhibitors of cyclin-dependent kinase 7 and uses thereof | 达纳-法伯癌症研究所股份有限公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-114206861-A | Fused heteroaryl compounds useful as RIPK1 inhibitors | 比西切姆有限公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-113383078-A | Oligonucleotide compositions and methods thereof | 波涛生命科学有限公司 | 2021-09-10 | — | — | CN | disclosed |
| WO-2021119081-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | VenatoRx Pharmaceuticals, Inc. (US) | 2021-06-17 | — | — | WO | disclosed |
| CN-107207514-B | Fused heteroaryl compounds and their use as TRK inhibitors | 康联制药有限公司 | 2020-01-24 | — | — | CN | disclosed |
| US-20030022811-A1 | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer | ABBOTT LABORATORIES | 2003-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230107941-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | HAVCR2, COPB1, HDLBP | ALDH1A1 3850/4885MCHR1 4201/4885LMNA 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.